陳柏任 助理教授 (Chen, Po-Jen)

- 電話:+886-7-3121101 ext.2139,2243 #16
- 傳真:+886-7-3234686
- 信箱:pjc@kmu.edu.tw
- 學歷:
- 國防醫學院 生命科學研究所 博士
- 長庚大學 醫學生物技術暨檢驗學系碩士班 碩士
- 中山醫學大學 生物醫學科學學系 學士
- 研究專長:
- 發炎免疫藥理學、癌症藥理學、天然藥物開發、腫瘤免疫微環境、分子細胞生物學
- 研究方向:
- 免疫調節之藥物開發、抗癌藥物開發、腫瘤免疫微環境之致病機轉研究與其藥物開發、改善代謝疾病之保健產品與藥物開發
教學
主負責專業課程
- 碩士班一年級:
參與其他專業課程
- 大學部醫學系、後醫學系:block 課程
- 大學部牙醫學系三年級:藥理學(含牙科藥理學)、藥理學實驗
- 大學部藥學系三年級:藥理學、藥理學實驗
- 大學部護理系二年級:藥理學
研究
1.台灣原生蘭科植物抗發炎活性成分開發與其改善乾癬之治療應用 (II)
成義合作計畫 (114/01/01-114/12/31)
2. 探討台灣白及天然物對大腸直腸癌與嗜中性白血球交互作用之影響及其療效評估 (3年)
國科會113年度專題研究計畫 (113/08/01-115/07/31)
3. 從石仙桃天然物開發鐵依賴死亡誘導劑及其治療大腸直腸癌之應用
大專學生研究計畫 (113/07/01-114/02/28)
4. 不易形成體脂肪之中藥新藥開發與其減重應用
義義合作計畫 (113/06/01-114/05/31)
5. 台灣原生蘭科植物抗發炎活性成分開發與其改善乾癬之治療應用 (I)
成義合作計畫 (113/01/01-113/12/31)
6. 開發台灣白及治療大腸直腸癌:療效評估與機轉研究
國科會112年度專題研究計畫 (112/08/01-113/07/31)
7. CT01植物成分對誘導白色脂肪組織褐化之研究
成義合作計畫 (112/01/01-112/12/31)
8. 研究與開發應用於治療大腸直腸癌之天然物
義義合作計畫 (111/05/01-112/04/30)
9. 探討嗜中性白血球在腫瘤免疫微環境中作為治療標靶之潛力
義大醫院專案研究計畫 (111/01/01-111/12/31)
10. 台灣白及有效成分用於治療急性肝損傷與急性呼吸窘迫症之臨床前研究 (3年)
國科會109年度專題研究計畫 (109/08/01-111/07/31)
11. 天然物抑制JNK訊號路徑在人類嗜中性白血球的抗發炎作用之研究
國科會108年度專題研究計畫 (108/01/01-108/12/31)
12. 沙參麥冬湯抑制小鼠急性肺損傷之功效探討
產學合作案 (109/12/20-110/05/31)
專利:
- Hwang TL, Chen PJ. Pharmaceutical composition and use for applying ribociclib in phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity. Patent. No.: US 11,351,172 B2, Date of Patent: Jun. 7, 2022
- 黃聰龍, 陳柏任。利博西林用於製備治療罹患磷酸二酯酶4介導疾病的患者的醫藥組合物的用途。中華民國發明第I769382號;專利權期間:20220701-20390620
- 黃聰龍、陳柏任。利博西林用于制备治疗罹患磷酸二酯酶4介导疾病的患者的医药组合物及用途。中華人民共和國發明專利號:ZL 2020 1 0078474. 3;專利權期間:20220419-20420418
- 黃聰龍、陳柏任、曾馨慧。帕博西林用於製備治療罹患疾病的患者的醫藥組合物的用途。中華民國發明第I737999號;專利權期間:20210901-20390528
- 黃聰龍, 陳柏任, 曾馨慧。帕博西林用於製備治療罹患疾病的患者及抑制磷脂醯肌醇3-激酶的活性的醫藥組合物及用途。中華人民共和國發明專利號:ZL 2020 1 0078609. 6;專利權期間:20220624-20420623
著作
- Chen SH, Chen CH, Lin HC, Yeh SA, Hwang TL*, Chen PJ*. Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis. Journal of Advanced Research, 2025 Jun; 72: 485-500 (IF: 13)
- Hemida N, El-Gamil DS, ElHady AK, Lin KC, Chang YH, Hilscher S, Schutkowski M, Ibrahim HS, Hamed MM, Chen SH, Chen CH, Abadi AH, Sippl W, Chen PJ*, Cheng YS, Abdel-Halim M*. Unlocking the potential of novel Tetrahydro-β-Carboline-based HDAC6 inhibitors for colorectal Cancer therapy: Design, synthesis and biological evaluation. Bioorganic Chemistry, 2025 Jun; 160: 108454.
- Fathya A, Allama A, ElHady AK, El-Gamil DS, Lin KC, Chang YH, Lee YH, Hilscher S, Schutkowski M, Ibrahim HS, Chen SH, Chen CH, Abadi AH, Sippl W, Chen PJ*, Cheng YS, Abdel-Halim M*. Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer. RSC Medicinal Chemistry, 2025 Jun; 16: 2754.
- Chang YH, Lee YC, Chen SH, Fang SY, Cheng TP, Chi CH, Tsai KC, Chen PJ*, Hung HY*. Discovery of a novel C2-functionalized chromen-4-one scaffold for the development of p38α MAPK signaling inhibitors to mitigate neutrophilic inflammatory responses. Biochemical Pharmacology, 2025 May; 235: 116806. (IF: 5.6)
- Chen YC, Lee YR, Chang YC, Wang YH, Fang SY, Lin CH*, Chen PJ*, Hwang TL*. Scutellaria barbata ameliorates acute respiratory distress syndrome by inhibiting neutrophil-mediated inflammatory responses. Journal of Ethnopharmacology, 2025 Apr; 346: 119653.
- Kuo SL, Su CH, Lai KH, Chang YC, You JS, Peng HH, Chen CH, Lin CC*, Chen PJ*, Hwang TL*. Guizhi Fuling Wan ameliorates concanavalin A-induced autoimmune hepatitis in mice. Biomedical Journal, 2025 Feb; 48(1):100731.
- Chen PJ, Chen SH, Chen YL, Wang YH, Lin CY, Chen CH, Tsai YF, and Hwang TL. Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome. Journal of Advanced Research, 2024 Aug; 62:229-243. (IF: 13)
- Mohamed NN#, Chen PJ#, Darwish SS, Su YC, Shiao MH, Gary A P, Abadi A, Engel M, Abdel-Halim M. N-benzylated 5-hydroxybenzothiophene-2-carboxamides as multitargeted Clk/Dyrk inhibitors and potential anticancer agents. Cancers, 2024 May; 16(11), 2033
- el-Rahman YAA#, Chen PJ#, ElHady AK, Chen SH, Lin HC, El-Gamil DS, Aboushady Y, Abadi1 AH, Abdel-Halim M, Engel M. Development of 5-hydroxybenzothiophene derivatives as multi-kinase inhibitors with potential anti-cancer activity. Future Medicinal Chemistry, 2024 May; 16(12):1239-1254.
- Chen PJ, Tseng HH, Wang YH, Fang SY, Chen SH, Chen CH, Tsai SC, Chang YC, Tsai YF, and Hwang TL. Palbociclib blocks neutrophilic PI3K activity to alleviate psoriasiform dermatitis. British Journal of Pharmacology, 2023 Aug; 180(16):2172-88 (IF: 7.7)
- Su YC, Lee WC, Wang CC, Yeh SA, Chen WH, and Chen PJ*. Targeting PI3K/AKT/mTOR signaling pathway as a radiosensitization in head and neck squamous cell carcinomas. International Journal of Molecular Sciences, 2022 Dec; 23(24), 15749.
- Wagdy R#, Chen PJ#, Hamed MM#, Darwish S, Chen SH, Abadi AH, Abdel-Halim M, Hwang TL, and Engel M. From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolinyl)-phenylthiourea derivatives as novel NF-κB inhibitors. Bioorganic Chemistry, 2022 Oct; 127, 105977.
- Darwish S#, Chen PJ#, Hamed MM#, Wagdy R, Chen SH, Abadi AH, Abdel-Halim M, Hwang TL, and Engel M. Development of (4-phenylamino)quinazoline alkylthiourea derivatives as novel NF-κB inhibitors. Pharmaceuticals, 2022 Jun; 15(7), 778.
- Chen YY#, Chen LY#, Chen PJ#, El-Shazly M, Peng BR, Chen YC, Su CH, Su JH, Sung PJ, Yen PZ, Wang LS, Lai KH. Probing Anti-Leukemic Metabolites from Marine-Derived Streptomyces sp. LY1209. Metabolites, 2022 Apr; 12(4), 320.
- Kao TI#, Chen PJ#, Wang YH, Tseng HH, Chang SH, Wu TS, Yang SH, Lee YT, Hwang TL. Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. British Journal of Pharmacology, 2021 Oct; 178(20):4069-4084. (IF: 7.7)
- Lai KH#, Chen PJ#, Chen CC, Yang SH, El-Shazly M, Chang YC, Wu YH, Wu YH, Wang YH, Hsieh HL, Hwang TL. Lophatherum gracile Brongn. attenuates neutrophilic inflammation through inhibition of JNK and calcium. Journal of Ethnopharmacology, 2021 Jan; 264:113224.
- Chen PJ, Kuo LM, Lai KH, Chang YC, Wu YH, Hwang TL. BAY 41-2272 attenuates the TGFβ1-induced CTGF expression via sGC-independent pathway in hepatic stellate cells. Biomedicines; 2020 Sep; 8(9):330.
- Liu FC#, Yu HP#, Chen PJ#, Yang HW, Chang SH, Tzeng CC, Cheng WJ, Chen YR, Chen YL, Hwang TL. A novel NOX2 inhibitor attenuates human neutrophil oxidative stress and ameliorates inflammatory arthritis in mice. Redox Biology, 2019 Sep; 26:101273. (IF: 11.9)
- Chen PJ, Ko IL, Lee CL, Hu HC, Chang FR, Wu YC, Leu YL, Wu CC, Lin CY, Pan CY, Tsai YF, Hwang TL. Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation. EBioMedicine, 2019 Feb; 40:528-40. (IF: 10.8)
- Kuo LM#, Chen PJ#, Sung PJ, Chang YC, Ho CT, Wu YH, Hwang TL. The bioactive extract of Pinnigorgia sp. induces apoptosis of hepatic stellate cells via ROS-ERK/JNK-caspase 3 signaling. Marine Drugs, 2018 Jan; 16(1):19-31.
- Chen PJ, Wang YL, Kuo LM, Lin CF, Chen CY, Tsai YF, Shen JJ, Hwang TL. Honokiol suppresses TNF-α-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IκBα. Scientific Reports, 2016 May; 23(6):26554.
- Chen PJ, Weng JY, Hsu PH, Shew JY, Huang YS, Lee WH. NPGPx modulates CPEB2-controlled HIF-1α RNA translation in response to oxidative stress. Nucleic Acids Research, 2015 Oct; 43(19):9393-404. (IF: 13.1)
- Chen PJ, Huang YS. CPEB2-eEF2 interaction impedes HIF-1α RNA translation. EMBO Journal, 2012 Feb; 31(4):959-71. (IF: 8.3)
研討會論文
- Chen PJ*, Chen SH, Hung HY, and Lee YC. Discovery of a novel formyl peptide receptor 1 antagonist for treating neutrophilic inflammation. The 39th Joint Annual Conference of Biomedical Science, Taiwan, 2025
- Chen PJ*. Bletilla formosana and its constituents as promising therapeutics via modulation of redox homeostasis. 2025中醫藥與天然藥物聯合學術研討會, 2025 (受邀演講)
- Chen PJ*. Advancing the development of drug candidates for neutrophilic inflammatory diseases. 第三十九屆生物醫學聯合學術年會台灣藥理學會, 2025 (受邀演講)
- Chen SH, Chen CH, Hsu CL, Chang YC, and Chen PJ*. Natural bibenzyl exerts mitotic inhibition in the treatment of nasopharyngeal carcinoma. The 145th Annual Meeting of the Pharmaceutical Society of Japan, Fukuoka, Japan, 2025
- Tsai SC, Lee CH, Hong YC, Liu HH, Lai KH, Lam SH, and Chen PJ*. Pholidota chinensis-derived dihydrophenanthrene prompts GPx4 inhibition and ferroptotic oxidative stress for treating colorectal cancer. The 39th Symposium on Natural Products and 24th Society for Free Radical Research-Taiwan, Taiwan, 2024 (Best Poster Award)
- Lai IJ, Lee YC, Hung LY, Yeh CJ, Liu HH, Lai KH, Chang YC, and Chen PJ*. Exploring prevention of body fat accumulation in traditional Chinese medicine from Rubiaceae. The 39th Symposium on Natural Products and 24th Society for Free Radical Research-Taiwan, Taiwan, 2024
- Kuo SL, Lin CC, Chen PJ*, and Hwang TL. Guizhi Fuling Wan employs antiapoptotic, antioxidant, and immunomodulatory protection against concanavalin A-induced autoimmune hepatitis in mice. The Society for Free Radical Research-Taiwan, Taiwan, 2023 (Best Poster Award)
- Chen PJ*, Chen SH, and Hwang TL. Drug repurposing of ribociclib in the treatment of inflammatory disease. The 19th World Congress of Basic and Clinical Pharmacology, Glasgow, UK, 2023
- Chen PJ*, Chen SH, Sie JY, and Hwang TL. The effects of a pure compound from Bletilla in the treatment of acute liver injury. The 37th Joint Annual Conference of Biomedical Science, Taiwan, 2023
- Huang YT, Lee YC, Chang YC, Chen PJ*. Development of anticancer marine products in colorectal cancer. The 37th International Symposium on Natural Products, The Society of Chinese Natural Medicine, Taiwan, 2022
- Tsai SC, Chen SH, Chen PJ*, and Hwang TL. CDK inhibitor serves as a new drug for treatment of neutrophilic psoriasiform dermatitis. The 36th Joint Annual Conference of Biomedical Science, Taiwan, 2022 (Distinguished Poster Prize of Tien Te Lee Biomedical Foundation)
- Chen PJ*. Recent advance in targeting inflammatory diseases. 中山醫學大學2021年基礎與應用科學和創新與創業研討會, 2021 (受邀演講)
- Chen PJ*, Chen SH, Tseng HH, and Hwang TL. CDK inhibitor ameliorates neutrophil-associated psoriasiform dermatitis by inhibiting PI3K activity. 14th Asia Pacific Federation of Pharmacologists, Pharmacological Society in Taiwan, Taiwan, 2021
- Chen PJ, Kao TI, and Hwang TL. Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. 14th Asia Pacific Federation of Pharmacologists, Pharmacological Society in Taiwan, Taiwan, 2021
- Chen PJ*. Opportunity of anti-inflammatory agents on cosmetics for skin disorders第十五屆亞洲化粧品科學家大會 (ASCS Conference), 2021 (受邀演講)
- Chen PJ, Lai KH, and Hwang TL. Lophatherum gracile Brongn. attenuates neutrophilic inflammation through inhibition of JNK and calcium. The 35th International Symposium on Natural Products, The Society of Chinese Natural Medicine, Taiwan, 2020 (Poster Award)
- Chen PJ and Hwang TL. A novel PDE4 inhibitor impedes psoriasis-like lesions via restricting neutrophilic inflammation. 16th International Workshop on Langerhans Cells, Mainz/Budenheim, Germany, 2019
European Journal of Immunology. 2019; 49 (Suppl. 2): 1–28 - Chen PJ and Hwang TL. A novel NOX2 inhibitor CYR5099 attenuates neutrophilic oxidative stress and inflammatory paw injury in mice. The 18th World Congress of Basic and Clinical Pharmacology, Kyoto, Japan, 2018
- Chen PJ, Lee CL, Chang FR, Wu YC, and Hwang TL. Targeting redox regulatory site of protein kinase B impedes neutrophilic inflammation. The 32nd International Symposium on Natural Products, The Society of Chinese Natural Medicine, Taiwan, 2017 (Best Poster Award)
- Chen PJ and Huang YS. CPEB2 interacts with eEF2 and impedes target RNA translation at elongation. The 16th Annual Meeting of the RNA Society, Kyoto, Japan, 2011 (Poster Award)